| 证券代码：301002 | 证券简称：崧盛股份 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：123159 | 债券简称：崧盛转债 | | 深圳市崧盛电子股份有限公司 关于向控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 深圳市崧盛电子股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召 开第三届董事会第十九次会议及第三届监事会第十四次会议、2025 年 5 月 19 日 召开 2024 年年度股东大会，审议通过了《关于 2025 年度拟向银行申请综合授信 额度及对子公司提供担保额度预计的议案》，同意公司对控股子公司深圳崧盛创 新技术有限公司（以下简称"崧盛创新"）向银行申请的综合授信业务提供不超 过人民币 10,000 万元（含本数）的担保额度，并接受崧盛创新其他股东暨公司关 联方——田年斌、王宗友及由田年斌担任执行事务合伙人的有限合伙企业按其对 崧盛创新的持股比例向公司提供的同等比例反担保。上述额度有效期为自 2024 年年度股东大会审议通过之日 ...

证券代码：301002 证券简称：崧盛股份 深圳市崧盛电子股份有限公司 投资者关系活动记录表 编号 2025-006 公司专注从事 LED 照明驱动电源近 15 年，目前已发展成为国内具备规模化 制造能力、数字化运营能力及全球供应能力的领先 LED 照明驱动电源生产 商，为响应"中国制造 2025"政策导向，抓住机器人、航空航天等先进制 造行业高速发展窗口期，在此背景下，公司与重庆精刚传动科技有限公司 共同出资设立深圳市崧盛机器人传动科技有限公司，其中公司以货币资金 出资人民币 550 万元，占注册资本的 55%，重庆精刚传动以货币资金出资 人民币 450 万元，占注册资本的 45%。 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系 | 媒体采访 业绩说明会 | | 活动类别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他 | | | 国泰君安、华夏基金、宏道投资、深圳天际线投资、世诚投资、前海人寿、 | | 参与单位名 | 煜德投资、建信基金、东方基金、上海德汇集团有限公司、杭州巨子、盈 | | 称 | 峰资本、鹏扬基金、中金公司、申万宏源 ...

| 证券代码：301002 | 证券简称：崧盛股份 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：123159 | 债券简称：崧盛转债 | | 3、截至 2025 年 6 月 30 日，公司剩余可转换公司债券张数为 2,943,365 张， 剩余可转换公司债券票面总额为人民币 294,336,500.00 元。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》的有关规定，深圳市崧盛电子股份有限 公司（以下简称"崧盛股份"或"公司"）现将 2025 年第二季度可转换公司债券 （以下简称"可转债"）转股及公司股份变动情况公告如下： 深圳市崧盛电子股份有限公司 关于 2025 年第二季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"崧盛转债"（债券代码：123159）转股期限为 2023 年 4 月 10 日至 2028 年 9 月 26 日；最新的转股价格为人民币 24.35 元/股。 2、2025 年第二季度 ...

Core Insights - The latest financing balance of the ChiNext market is 358.47 billion yuan, with a week-on-week increase of 3.90 billion yuan, indicating a positive trend in market financing activity [1] - A total of 40 stocks saw their financing balances increase by over 10%, while 16 stocks experienced a decline of more than 10% [1] Financing Balance Overview - As of June 30, the total margin balance for ChiNext stocks reached 359.50 billion yuan, marking an increase of 3.94 billion yuan from the previous trading day, continuing a six-day upward trend [1] - The financing balance specifically increased to 358.47 billion yuan, with a week-on-week rise of 3.90 billion yuan, also reflecting six consecutive days of growth [1] - The margin trading balance for short selling reached 1.03 billion yuan, with a week-on-week increase of 35.32 million yuan [1] Stocks with Significant Financing Balance Increases - Among the 527 stocks with increased financing balances, the stock with the highest increase is Huaren Health, which saw a financing balance of 95.80% growth, reaching 95.42 million yuan, and its stock price rose by 4.61% [1][3] - Other notable stocks with significant increases include Zhongguang Fanglei (72.52% increase) and Songsheng Co., Ltd. (62.77% increase) [1][3] Market Performance of Stocks with Increased Financing - Stocks with financing balance increases of over 10% averaged a rise of 5.10% on the same day, with 33 stocks experiencing gains, including three stocks that hit the daily limit [2] - The top gainers included Songsheng Co., Ltd. (13.73%), Guanshang Technology (13.22%), and Xinyu Guoke (11.85%) [2] Stocks with Decreased Financing Balances - A total of 406 stocks saw a decrease in financing balances, with 16 stocks experiencing declines of over 10% [4] - Wan Sheng Intelligent had the largest decrease, with a financing balance of 85.13 million yuan, down by 22.68% [4] - Other significant declines were observed in Ruina Intelligent (21.75% decrease) and Linuo Pharmaceutical Packaging (19.14% decrease) [4] Summary of Stocks with Decreased Financing Balances - The stocks with the largest decreases in financing balances include: - Wan Sheng Intelligent: 85.13 million yuan, -22.68% [4][5] - Ruina Intelligent: 46.40 million yuan, -21.75% [4][5] - Linuo Pharmaceutical Packaging: 158.80 million yuan, -19.14% [4][5]

Market Overview - The Shanghai Composite Index closed at 3444.43 points, above the five-day moving average, with a gain of 0.59% [1] - The total trading volume of A-shares reached 1,517.37 billion yuan [1] Stocks Performance - A total of 664 A-shares have surpassed the five-day moving average, indicating positive momentum [1] - Notable stocks with significant deviation rates include: - Morningstar Airlines (15.14%) - Xiangyu Medical (14.86%) - Qifeng Precision (13.27%) [1][2] - Stocks with smaller deviation rates that just crossed the five-day moving average include: - China Duty Free Group - Shanghai Yizhong - Shanjin International [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the five-day moving average: - Morningstar Airlines: 19.99% increase, 15.14% deviation [2] - Xiangyu Medical: 20.01% increase, 14.86% deviation [2] - Qifeng Precision: 17.25% increase, 13.27% deviation [2] - Other notable stocks include: - Lianjian Optoelectronics: 19.92% increase, 10.74% deviation [2] - Songsheng Co.: 13.73% increase, 10.55% deviation [2]

Core Viewpoint - The A-share market shows a mixed performance with 476 stocks breaking through the five-day moving average, indicating potential investment opportunities in certain sectors [1] Group 1: Market Overview - As of 10:29 AM, the Shanghai Composite Index is at 3432.93 points, below the five-day moving average, with a fluctuation of 0.25% [1] - The total trading volume of A-shares today is 693.146 billion yuan [1] Group 2: Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Morningstar Aviation (晨曦航空) with a deviation of 15.14% and a price increase of 19.99% [2] - Qifeng Precision (七丰精工) with a deviation of 11.69% and a price increase of 15.15% [2] - Awatech (阿为特) with a deviation of 10.02% and a price increase of 14.90% [2] - Other notable stocks with significant price increases and deviations include: - Xiongtai Technology (雄帝科技) with an 11.52% increase and an 8.85% deviation [2] - Songsheng Co. (崧盛股份) with a 10.85% increase and an 8.36% deviation [2] Group 3: Additional Stocks with Positive Performance - Other stocks showing positive performance and deviations include: - Lijun Co. (利君股份) with a 9.97% increase and a 7.69% deviation [2] - Xiangyu Medical (翔宇医疗) with a 10.41% increase and a 7.66% deviation [2] - Chengfei Integration (成飞集成) with a 10.00% increase and a 7.58% deviation [2]

| 证券代码：301002 | 证券简称：崧盛股份 | 公告编号：2025-035 | | --- | --- | --- | | 债券代码：123159 | 债券简称：崧盛转债 | | 深圳市崧盛电子股份有限公司 深圳市崧盛电子股份有限公司（以下简称"公司"）拟对外投资设立控股 子公司，现将相关情况公告如下： 公司拟与重庆精刚传动科技有限公司（以下简称"重庆精刚传动"）共同出 资 1,000万元设立深圳市崧盛机器人传动科技有限公司（最终名称以工商登记为 准），其中公司以货币资金出资人民币 550 万元，占注册资本的 55%；重庆精刚 关于对外投资设立控股子公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 风险提示： 1、本次拟投资设立的控股子公司目前尚处于工商设立阶段，尚无研发成果 及专利技术积累，后续投资进度、产品研发进程及产品商业化落地情况尚存在 不确定性，敬请广大投资者谨慎决策，注意投资风险。 2、本次拟投资设立的控股子公司后续可能存在研发及资产投入需求较大， 但研发成果转化及市场开拓存在较大不确定性风险，进而导致存在研发产业化 效益不达预期 ...

| | | 深圳市崧盛电子股份有限公司 关于签署技术开发合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次签署的技术开发合同确立了双方的合作计划，具体实施进度和最终 成果尚存在不确定性，敬请广大投资者谨慎决策，注意投资风险。 2、本次技术开发合同的签署不会对公司本年度财务状况及经营业绩构成重 大影响，对公司未来年度经营业绩的影响将视双方后续项目的实施进展情况确 定。 3、公司将及时针对本次合同的重大进展履行信息披露程序，并在定期报告 中披露重大合同的履行情况。 一、合同签署概况 近日，深圳市崧盛电子股份有限公司（以下简称"公司"）与重庆精刚传 动科技有限公司（以下简称"重庆精刚传动"）针对"机器人谐波减速器及智 能关节技术开发应用"项目签署《技术开发合同》（以下简称"合同"），其 中公司提供研发经费共计人民币 1,200 万元，重庆精刚传动负责组建研发团队及 技术攻关。实现设计开发具备高精度、轻量化、智能化等高性能特性的谐波减 速器、智能关节模组及关键零部件，并实现在机器人等工业领域的批量应用的 开发目标。 统一社会信用代码：91 ...

信用等级通知书 东方金诚债跟踪评字【2025】0058 号 深圳市崧盛电子股份有限公司： 东方金诚国际信用评估有限公司根据跟踪评级安排对贵公司及"崧 盛转债"的信用状况进行了跟踪评级，经信用评级委员会评定，此 次跟踪评级维持贵公司主体信用等级为 AA-，评级展望为稳定，同 时维持"崧盛转债"信用等级为 AA-。 东方金诚国际信用评估有限公司 信评委主任 二〇二五年六月九日 东方金诚债跟踪评字【2025】0058 号 信用评级报告声明 为正确理解和使用东方金诚国际信用评估有限公司（以下简称"东方金诚"）出具的 信用评级报告（以下简称"本报告"），声明如下： 1.本次评级为委托评级，东方金诚与受评对象不存在任何影响本次评级行为独立、客 观、公正的关联关系，本次项目评级人员与评级对象之间亦不存在任何影响本次评级 行为独立、客观、公正的关联关系。 2.本次评级中，东方金诚及其评级人员遵照相关法律、法规及监管部门相关要求，充 分履行了勤勉尽责和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的 原则。 3.本评级报告的结论，是按照东方金诚的评级流程及评级标准做出的独立判断，未受 评级对象和第三方组织或个人的干预和 ...

Group 1 - The company held its 15th meeting of the 3rd Supervisory Board on June 4, 2025, which was conducted in accordance with relevant laws and regulations [1] - The Supervisory Board approved the proposal to cancel part of the unvested restricted stock from the 2023 incentive plan, confirming that the decision complies with legal requirements and will not negatively impact the company's financial status or shareholder interests [1] - The voting results for the cancellation proposal were unanimous, with 3 votes in favor and no opposition or abstentions [1] Group 2 - The Supervisory Board also approved the adjustment of the grant price for the 2023 restricted stock incentive plan, stating that this adjustment is within the authorization granted by the shareholders and does not harm the interests of the company or its shareholders [2] - The voting results for the price adjustment proposal were also unanimous, with 3 votes in favor and no opposition or abstentions [2]